Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Uncategorized

Citigroup Upgrades CRH to Buy

Citigroup analyst Ephrem Ravi upgrades CRH (NYSE:CRH) from Neutral to Buy.

byBenzinga Newsdesk

May 12, 2021

1 minute read

Citigroup analyst Ephrem Ravi upgrades CRH (NYSE:CRH) from Neutral to Buy.

Applied DNA Initiates Analytical Validation Of PCR-based Diagnostic Test Specific To Monkeypox Virus

By Benzinga Newsdesk

Today, 8:44 PM

Applied DNA Sciences, Inc. (NASDAQ:APDN) (the "Company"), a leader in polymerase chain reaction ("PCR")-based technologies, announced that its wholly-owned clinical laboratory subsidiary, Applied

APDN

Apple Shuts 8 Shops Amid COVID-19 Resurgence: Report

By Anusuya Lahiri

Today, 8:44 PM

Apple Inc (NASDAQ:AAPL) temporarily shuttered at least eight retail stores in the U.S. and Canada since December 21 as…

AAPL

Keybanc Maintains Overweight on UDR, Raises Price Target to $55

By Benzinga Newsdesk

Today, 8:44 PM

Keybanc analyst Austin Wurschmidt maintains UDR (NYSE:UDR) with a Overweight and raises the price target from $46 to $55.

UDR

Piper Sandler Maintains Overweight on Alteryx, Raises Price Target to $87

By Benzinga Newsdesk

Today, 8:44 PM

Piper Sandler maintains Alteryx (NYSE:AYX) with a Overweight and raises the price target from $85 to $87.

AYX

Citigroup Upgrades CRH to Buy

Related Posts

Applied DNA Initiates Analytical Validation Of PCR-based Diagnostic Test Specific To Monkeypox Virus

Apple Shuts 8 Shops Amid COVID-19 Resurgence: Report

Keybanc Maintains Overweight on UDR, Raises Price Target to $55

Piper Sandler Maintains Overweight on Alteryx, Raises Price Target to $87